Back to search
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Clinicaltrials.gov:
EU CTIS:
#2024-519493-39-00
Other:
#42756493BLC3005
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Non-Muscle Invasive Bladder Neoplasms
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Gemcitabine
Mitomycin C
TAR-210
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
September 10, 2025
Trial end date
March 16, 2032
CT.gov ID
#NCT06919965
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Argentina,
- Belgium,
- Brazil,
- China,
- France,
- Germany,
- Greece,
- Israel,
- Italy,
- Japan,
- Netherlands,
- South Korea,
- Spain,
- United Kingdom,
- United States
Loading...
Enrolling
Brescia, Italy, 25123
Enrolling
Ghent, Belgium, 9000
Enrolling
Roeselare, Belgium, 8800
Enrolling
Syracuse, New York, United States, 13210
Enrolling
Chicago Ridge, Illinois, United States, 60451
Enrolling
Thessaloniki, Greece, 57001
Enrolling
Saint-Grégoire, France, 35768
Enrolling
Paris, France, 75013
Enrolling
Nijmegen, Netherlands, 6532 SZ
Enrolling
Regensburg, Germany, 93053
Enrolling
Haifa, Israel, 3436212
Enrolling
Myrtle Beach, South Carolina, United States, 29572
Enrolling
Córdoba, Argentina, X5000KPH
Enrolling
Cheongju-si, South Korea, 28644
Enrolling
Bergamo, Italy, 24125
Enrolling
Quint-Fonsegrives, France, 31130
Enrolling
Lakewood, Colorado, United States, 80228
Enrolling
Royal Oak, Michigan, United States, 48073
Enrolling
Centerville, Ohio, United States, 45459
Enrolling
Naples, Italy, 80131
Enrolling
Funabashi Shi, Japan, 273 8588
Enrolling
São José do Rio Preto, Brazil, 15090 000
Enrolling
São Paulo, Brazil, 01246 000
Enrolling
Thessaloniki, Greece, 56429
Enrolling
Athens, Greece, 115 27
Enrolling
Atlanta, Georgia, United States, 30328
Enrolling
Plymouth, Massachusetts, United States, 02360
Enrolling
Villejuif, France, 94800
Enrolling
Hakodate, Japan, 040 8611
Enrolling
Middleburg Heights, Ohio, United States, 44130
Enrolling
Brussels, Belgium, 1070
Enrolling
Paris, France, 75014
Enrolling
Paris, France, 75010
Enrolling
A Coruña, Spain, 15006
Enrolling
Málaga, Spain, 29010
Enrolling
Ferrol, Spain, 15405
Enrolling
Barcelona, Spain, 08036
Enrolling
Castellon, Spain, 12004
Enrolling
Cadiz, Spain, 11009
Enrolling
Madrid, Spain, 28041
Enrolling
Jerez de la Frontera, Spain, 11407
Enrolling
Sabadell, Spain, 08208
Enrolling
Presidente Prudente, Brazil, 19013-050
Enrolling
Buenos Aires, Argentina, C1419AHN
Enrolling
Cottingham, United Kingdom, HU16 5JQ
Enrolling
Marseille, France, 13009
Enrolling
Buenos Aires, Argentina, C1426ANZ
Enrolling
Caba, Argentina, C1425
Enrolling
Roma, Italy, 00144
Enrolling
Bunkyō City, Japan, 113 8431
Enrolling
Leverkusen, Germany, 51375
Enrolling
Athens, Greece, 115 27
Enrolling
Natal, Brazil, 59062 000
Enrolling
Stevenage, United Kingdom, SG1 4AB
Enrolling
Herne, Germany, 44625
Enrolling
Kfar Saba, Israel, 44281
Enrolling
Lancaster, Pennsylvania, United States, 17604
Enrolling
Bala-Cynwyd, Pennsylvania, United States, 19004
Enrolling
Nanjing, China, 210008
Enrolling
Voorhees Township, New Jersey, United States, 08043
Enrolling
Springfield, Oregon, United States, 97477
Enrolling
Udine, Italy, 33100
Enrolling
Milan, Italy, 20132
Enrolling
Beijing, China, 100034
Enrolling
Petah Tikva, Israel, 4941492
Enrolling
Nijmegen, Netherlands, 6525 GA
Enrolling
Haifa, Israel, 3109601
Enrolling
São Paulo, Brazil, 01323 010
Enrolling
Surrey, United Kingdom, SM2 5PT
Enrolling
Genova, Italy, 16149
Enrolling
Gangnam Gu, South Korea, 06351
Enrolling
Rosario, Argentina, 2000
Enrolling
Seongnam-si, South Korea, 13620
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03722
Enrolling
Ramat Gan, Israel, 52621
Enrolling
Athens, Greece, 15126
Enrolling
Southampton, United Kingdom, SO16 6HU
Enrolling
London, United Kingdom, EC1A 7BE
Enrolling
Kawasaki, Japan, 216 8511
Enrolling
Nürtingen, Germany, 72622
Enrolling
Guangzhou, China, 510260
Enrolling
Tel Aviv, Israel, 64239
Enrolling
Germantown, Tennessee, United States, 38138
Enrolling
Ningbo, China, 315020
Enrolling
Wenzhou, China, 325000
Enrolling
Minatoku, Japan, 105 8471
Enrolling
Tianjin, China, 300211
Enrolling
Chengdu, China, 610014
Enrolling
Cincinnati, Ohio, United States, 45212
Enrolling
Sakura, Japan, 285-8741
Enrolling
Wuhan, China, 430030
Enrolling
Cologne, Germany, 50937
Enrolling
Mannheim, Germany, 68167
Enrolling
Leuven, Belgium, 3000
Enrolling
Pittsburgh, Pennsylvania, United States, 15232
Enrolling
Austin, Texas, United States, 78745
Enrolling
San Antonio, Texas, United States, 78229
Enrolling
Carmel, Indiana, United States, 46032
Enrolling
Chengdu, China, 610093
Enrolling
Yokohama, Japan, 232 0024
Enrolling
Yokohama, Japan, 221 0855
Enrolling
Genk, Belgium, 3600
Completed
Omaha, Nebraska, United States, 68114
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
